Replicate Bioscience: Funding, Investors & Team (Oct 2026)
Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) technology to enhance the effectiveness of RNA-based therapeutics beyond traditional mRNA approaches. Its platform is designed to deliver stronger biological activity, more durable immune responses, and an improved therapeutic index. The company’s lead program, RBI-4000, an srRNA-based rabies vaccine, has shown protective immunity at lower doses than any mRNA or srRNA vaccine reported to date in Phase I studies. Backed by Apple Tree Partners, Replicate is building a diverse pipeline of srRNA vaccines and therapeutics supported by a proprietary, customizable viral vector library. With extensive expertise in srRNA and integrated development capabilities, the company aims to broaden the application of RNA therapies across infectious diseases, immunology, and immuno-oncology.
Replicate Bioscience has raised $10.0M across 2 funding rounds on record, the most recent an undisclosed round of $3.0M announced in Jun 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Replicate Bioscience Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Replicate Bioscience Funding Rounds
Replicate Bioscience raised $7.0M in an undisclosed round announced in Jan 2026.
5 months later, an undisclosed round of $3.0M was announced in Jun 2026.
Replicate Bioscience Founders and Leadership Team
Contact details for the Replicate Bioscience team: 1 of 1 has an email address on file.
Start 14-day free trial →Replicate Bioscience Funding Compared to Other Biotechnology Startups
Replicate Bioscience's latest round of $3.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Replicate Bioscience in Biotechnology and San Diego
Companies Similar to Replicate Bioscience
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Replicate Bioscience Funding FAQs
What does Replicate Bioscience do?
Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) technology to enhance the effectiveness of RNA-based therapeutics beyond traditional mRNA approaches. Its platform is designed to deliver stronger biological activity, more durable immune responses, and an improved therapeutic index. The company’s lead program, RBI-4000, an srRNA-based rabies vaccine, has shown protective immunity at lower doses than any mRNA or srRNA vaccine reported to date in Phase I studies. Backed by Apple Tree Partners, Replicate is building a diverse pipeline of srRNA vaccines and therapeutics supported by a proprietary, customizable viral vector library. With extensive expertise in srRNA and integrated development capabilities, the company aims to broaden the application of RNA therapies across infectious diseases, immunology, and immuno-oncology.
How much funding has Replicate Bioscience raised?
Replicate Bioscience has raised $10.0M across 2 rounds on record. The most recent is an undisclosed round of $3.0M announced in Jun 2026.
When did Replicate Bioscience last raise funding?
Replicate Bioscience's most recent funding round on record is an undisclosed round of $3.0M, announced in Jun 2026.
Who founded Replicate Bioscience?
FundedIQ lists Nathaniel Wang (Founder) at Replicate Bioscience.
Where is Replicate Bioscience headquartered?
Replicate Bioscience is based in San Diego, California, United States.
How many employees does Replicate Bioscience have?
Replicate Bioscience is in the 11-50 employee band.
How does Replicate Bioscience's funding compare to other Biotechnology startups?
Replicate Bioscience's latest round of $3.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Replicate Bioscience Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Replicate Bioscience is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.